1. [Glioblastoma That Does Not Improve with Standard Treatment: Poor Prognostic Factors and Future Perspectives].
- Author
-
Narita Y
- Subjects
- Aged, Antineoplastic Agents, Alkylating therapeutic use, DNA Methylation, Humans, Prognosis, Retrospective Studies, Temozolomide therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms therapy, Glioblastoma drug therapy, Glioblastoma therapy
- Abstract
The 5-year survival of glioblastoma (GBM) is at approximately 15%, and prognostic factors of GBM are age, Karnofsky performance status (KPS), extent of resection, and MGMT promoter methylation status. The reasons for the poor prognosis of GBM are as follows: 1)median age of onset of GBM is 68 years; 2)half of the patients have KPS≤70; 3)rapid growth of the tumor; 4)half of the patients undergo total resection; and 5)available drugs are only temozolomide and bevacizumab. The comprehensive genome profiling test is performed to analyze exome gene mutations, amplifications, deletions, and fusion gene expression in tumor tissues with a next-generation sequencer to identify tumor-specific driver genes. This test has been covered by public medical insurance for patients with cancer, including malignant brain tumors, in Japan since 2019. It detects the driver genes of GBM, such as BRAF and FGFR gene mutations, leading to clinical application by those inhibitors.
- Published
- 2022
- Full Text
- View/download PDF